工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:FOXO1 in cancer: context-dependent roles, microRNA regulation, and therapeutic opportunities.
FOXO1 in cancer: context-dependent roles, microRNA regulation, and therapeutic opportunities.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
叉头框蛋白O1(FOXO1)是一种关键转录因子,参与调控细胞凋亡、细胞周期阻滞、氧化应激反应和代谢稳态。尽管FOXO1传统上被认为发挥肿瘤抑制因子的作用,但新近证据揭示其在特定情境下具有致癌功能,尤其是在肿瘤干细胞(CSCs)和治疗抵抗性癌症中。本综述探讨了microRNA(miRNAs)调控FOXO1表达与活性的复杂调控网络。致癌性miRNAs下调FOXO1,或通过PI3K/AKT通路促进其在细胞质中的滞留,从而增强肿瘤增殖、上皮-间质转化和转移。相反,抑瘤性miRNAs上调或激活FOXO1,重新建立细胞周期阻滞和细胞凋亡。除肿瘤抑制作用外,FOXO1还支持CSCs的维持和治疗抵抗,凸显了其功能的双重性。
值得注意的是,有研究显示FOXO1过表达可改善嵌合抗原受体(CAR)T细胞在实体瘤中的代谢适应性和持久性,提示其具有增强免疫治疗的潜力。靶向miRNA-FOXO1轴的治疗方法,包括miRNA模拟物、抑制剂、磷酸酶调节剂和激酶抑制剂,前景广阔,但需精准施用,以避免对非恶性组织产生不良影响。全面理解FOXO1在不同情境下的特异性作用,对推进癌症靶向治疗至关重要。
Forkhead box O1 (FOXO1) is a key transcription factor involved in regulating apoptosis, cell cycle arrest, oxidative stress responses, and metabolic homeostasis. Although FOXO1 traditionally functions as a tumour suppressor, emerging evidence reveals its context-dependent oncogenic role, particularly in cancer stem cells (CSCs) and therapy-resistant cancers. This review explores the complex regulatory network by which microRNAs (miRNAs) modulate FOXO1 expression and activity.
Oncogenic miRNAs downregulate FOXO1 or promote its cytoplasmic sequestration via the PI3K/AKT pathway, enhancing tumour proliferation, epithelial-mesenchymal transition, and metastasis. In contrast, tumour-suppressive miRNAs upregulate or activate FOXO1, reinstating cell cycle arrest and apoptosis. Beyond its tumour-suppressive roles, FOXO1 also supports CSC maintenance and therapeutic resistance, highlighting the duality of its function.
Notably, FOXO1 overexpression has been shown to improve the metabolic fitness and persistence of chimeric antigen receptor (CAR) T cells in solid tumours, suggesting potential for immunotherapy enhancement. Therapeutic approaches targeting the miRNA-FOXO1 axis, including miRNA mimics, inhibitors, phosphatase modulators, and kinase inhibitors, are promising but require precision to avoid undesirable effects in non-malignant tissues. Comprehensive understanding of FOXO1 s context-specific roles is essential for advancing targeted cancer therapies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。